These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 36613920)

  • 1. TSLP as a Potential Therapy in the Treatment of CRLF2 B Cell Acute Lymphoblastic Leukemia.
    Alkashgari HR; Ruiz-Jimenez C; Stoian C; Coats JS; Baez I; Chirshev E; Martinez SR; Dovat S; Francis-Boyle OL; Casiano CA; Payne KJ
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel xenograft model to study the role of TSLP-induced CRLF2 signals in normal and malignant human B lymphopoiesis.
    Francis OL; Milford TA; Martinez SR; Baez I; Coats JS; Mayagoitia K; Concepcion KR; Ginelli E; Beldiman C; Benitez A; Weldon AJ; Arogyaswamy K; Shiraz P; Fisher R; Morris CL; Zhang XB; Filippov V; Van Handel B; Ge Z; Song C; Dovat S; Su RJ; Payne KJ
    Haematologica; 2016 Apr; 101(4):417-26. PubMed ID: 26611474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aberrant STAT5 and PI3K/mTOR pathway signaling occurs in human CRLF2-rearranged B-precursor acute lymphoblastic leukemia.
    Tasian SK; Doral MY; Borowitz MJ; Wood BL; Chen IM; Harvey RC; Gastier-Foster JM; Willman CL; Hunger SP; Mullighan CG; Loh ML
    Blood; 2012 Jul; 120(4):833-42. PubMed ID: 22685175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differences in signaling through the B-cell leukemia oncoprotein CRLF2 in response to TSLP and through mutant JAK2.
    van Bodegom D; Zhong J; Kopp N; Dutta C; Kim MS; Bird L; Weigert O; Tyner J; Pandey A; Yoda A; Weinstock DM
    Blood; 2012 Oct; 120(14):2853-63. PubMed ID: 22915648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling.
    Brown VI; Hulitt J; Fish J; Sheen C; Bruno M; Xu Q; Carroll M; Fang J; Teachey D; Grupp SA
    Cancer Res; 2007 Oct; 67(20):9963-70. PubMed ID: 17942929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting TSLP-Induced Tyrosine Kinase Signaling Pathways in
    Sia KCS; Zhong L; Mayoh C; Norris MD; Haber M; Marshall GM; Raftery MJ; Lock RB
    Mol Cancer Res; 2020 Dec; 18(12):1767-1776. PubMed ID: 32801162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of amino acids in transmembrane domains of mutated cytokine receptor-like factor 2 and interleukin-7 receptor α required for constitutive signal transduction.
    Yamamoto R; Segawa R; Kato H; Niino Y; Sato T; Hiratsuka M; Hirasawa N
    Biochim Biophys Acta Biomembr; 2024 Oct; 1866(7):184359. PubMed ID: 38862034
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Site-directed mutagenesis reveals a unique requirement for tyrosine residues in IL-7Ralpha and TSLPR cytoplasmic domains in TSLP-dependent cell proliferation.
    Zhong J; Pandey A
    BMC Immunol; 2010 Feb; 11():5. PubMed ID: 20144186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Requirement for stat5 in thymic stromal lymphopoietin-mediated signal transduction.
    Isaksen DE; Baumann H; Trobridge PA; Farr AG; Levin SD; Ziegler SF
    J Immunol; 1999 Dec; 163(11):5971-7. PubMed ID: 10570284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functional screening identifies CRLF2 in precursor B-cell acute lymphoblastic leukemia.
    Yoda A; Yoda Y; Chiaretti S; Bar-Natan M; Mani K; Rodig SJ; West N; Xiao Y; Brown JR; Mitsiades C; Sattler M; Kutok JL; DeAngelo DJ; Wadleigh M; Piciocchi A; Dal Cin P; Bradner JE; Griffin JD; Anderson KC; Stone RM; Ritz J; Foà R; Aster JC; Frank DA; Weinstock DM
    Proc Natl Acad Sci U S A; 2010 Jan; 107(1):252-7. PubMed ID: 20018760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential efficacy and prognosis of silencing the CRLF2‑mediated AKT/mTOR pathway in pediatric acute B‑cell lymphoblastic leukemia.
    Jiang M; Zou X; Lu L
    Oncol Rep; 2019 Feb; 41(2):885-894. PubMed ID: 30535452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inflammatory cytokine TSLP stimulates platelet secretion and potentiates platelet aggregation via a TSLPR-dependent PI3K/Akt signaling pathway.
    Dong J; Lin J; Wang B; He S; Wu C; Kushwaha KK; Mohabeer N; Su Y; Fang H; Huang K; Li D
    Cell Physiol Biochem; 2015; 35(1):160-74. PubMed ID: 25591759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia.
    Maude SL; Tasian SK; Vincent T; Hall JW; Sheen C; Roberts KG; Seif AE; Barrett DM; Chen IM; Collins JR; Mullighan CG; Hunger SP; Harvey RC; Willman CL; Fridman JS; Loh ML; Grupp SA; Teachey DT
    Blood; 2012 Oct; 120(17):3510-8. PubMed ID: 22955920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A recombinant antibody fragment directed to the thymic stromal lymphopoietin receptor (CRLF2) efficiently targets pediatric Philadelphia chromosome-like acute lymphoblastic leukemia.
    Mohamed SMA; Wohlmann A; Schofield P; Sia KCS; McCalmont H; Savvides SN; Verstraete K; Kavallaris M; Christ D; Friedrich KH; Bayat N; Lock RB
    Int J Biol Macromol; 2021 Nov; 190():214-223. PubMed ID: 34481852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome.
    Schwartzman O; Savino AM; Gombert M; Palmi C; Cario G; Schrappe M; Eckert C; von Stackelberg A; Huang JY; Hameiri-Grossman M; Avigad S; Te Kronnie G; Geron I; Birger Y; Rein A; Zarfati G; Fischer U; Mukamel Z; Stanulla M; Biondi A; Cazzaniga G; Vetere A; Wagner BK; Chen Z; Chen SJ; Tanay A; Borkhardt A; Izraeli S
    Proc Natl Acad Sci U S A; 2017 May; 114(20):E4030-E4039. PubMed ID: 28461505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of the surface expression of thymic stromal lymphopoietin receptor with the presence of CRLF2 gene rearrangements in children with B-lineage acute lymphoblastic leukemia.
    Demina I; Zerkalenkova E; Soldatkina O; Kazakova A; Semchenkova A; Goncharova M; Novichkova G; Maschan M; Karachunskiy A; Olshanskaya Y; Popov A
    Int J Lab Hematol; 2023 Jun; 45(3):337-343. PubMed ID: 36748719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of thymic stromal lymphopoietin in CD8+ T cell homeostasis.
    Rochman Y; Leonard WJ
    J Immunol; 2008 Dec; 181(11):7699-705. PubMed ID: 19017958
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of thymic stromal lymphopoietin (TSLP) receptor inhibits TSLP-driven proliferation and signalling in lymphoblasts from a subset of B-precursor ALL patients.
    Vetter T; Borowski A; Wohlmann A; Ranjan N; Kuepper M; Badura S; Ottmann OG; Friedrich K
    Leuk Res; 2016 Jan; 40():38-43. PubMed ID: 26652578
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRLF2 rearrangement in Ph-like acute lymphoblastic leukemia predicts relative glucocorticoid resistance that is overcome with MEK or Akt inhibition.
    Meyer LK; Delgado-Martin C; Maude SL; Shannon KM; Teachey DT; Hermiston ML
    PLoS One; 2019; 14(7):e0220026. PubMed ID: 31318944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia.
    Russell LJ; Capasso M; Vater I; Akasaka T; Bernard OA; Calasanz MJ; Chandrasekaran T; Chapiro E; Gesk S; Griffiths M; Guttery DS; Haferlach C; Harder L; Heidenreich O; Irving J; Kearney L; Nguyen-Khac F; Machado L; Minto L; Majid A; Moorman AV; Morrison H; Rand V; Strefford JC; Schwab C; Tönnies H; Dyer MJ; Siebert R; Harrison CJ
    Blood; 2009 Sep; 114(13):2688-98. PubMed ID: 19641190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.